A Modular Approach to Obtain HER2-Targeting DM1-Loaded Nanoparticles for Gastric Cancer Therapy

A Modular Approach to Obtain HER2-Targeting DM1-Loaded Nanoparticles for Gastric Cancer Therapy

Saved in:

Bibliographic Details
Main Authors:	Hui Zhang, Lijiao Guo, Xue Li, Hongtao Liu, Zibin Zhao, Guangling Ji, Yue Huang, Xiaodong Wang
Format:	Article
Language:	English
Published:	American Chemical Society 2024-11-01
Series:	ACS Omega
Online Access:	https://doi.org/10.1021/acsomega.4c07442
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Enhanced cytotoxicity of T-DM1 in HER2-low carcinomas via autophagy inhibition.
by: Jinghui Zhang, et al.
Published: (2025-01-01)

Docetaxel-loaded pH/ROS dual-responsive nanoparticles for the targeted treatment of gastric cancer
by: Junjia Wu, et al.
Published: (2025-02-01)

HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy
by: Qiangzu Shao, et al.
Published: (2025-03-01)

Clinical characteristics, treatment, and survival of thrombocytopenia induced by T-DM1 in early HER2-positive breast cancer
by: Fang Wang, et al.
Published: (2025-07-01)

Pyrotinib promotes the antitumor effect of T-DM1 by increasing drug endocytosis in HER2-positive breast cancer
by: Wenjun Ren, et al.
Published: (2025-05-01)

Real-World Analysis of the Efficacy and Adverse Events of T-DM1 in Chinese Patients With HER2-Positive Breast Cancer
by: Gu H, et al.
Published: (2025-02-01)

Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?
by: Wiebren Tjalma, et al.
Published: (2025-06-01)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
by: Yu Ishimine, et al.
Published: (2015-01-01)

Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer
by: Heves Surmeli, et al.
Published: (2025-06-01)

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy
by: Charles E. Geyer, Jr., et al.
Published: (2025-06-01)

T-DM1 with concurrent radiotherapy in HER2-positive breast cancer: preclinical evaluation and mechanisms, prediction, and exploration of adverse effects
by: Guangmin Wan, et al.
Published: (2025-05-01)

Targeting PGK1 as a Novel strategy to regulate the sensitivity of HER2 positive gastric cancer to lapatinib
by: Xiaochen Ni, et al.
Published: (2025-07-01)

Her2+ and b-HCG Producing Undifferentiated Gastric Adenocarcinoma
by: Sahar Eivaz-Mohammadi, et al.
Published: (2014-01-01)

Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer
by: Abbey Zidel, et al.
Published: (2025-05-01)

HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis.
by: Guo-Dong Cao, et al.
Published: (2016-01-01)

Mathematical model of technological process of permanent joints obtaining in the modular type robots construction
by: I. Sh. Nevliudov, et al.
Published: (2019-06-01)

Real-time assessment of circulating tumor cells refines the indication for HER2-targeted therapy in metastatic gastric cancer
by: Yasuaki Kimura, et al.
Published: (2025-07-01)

Evolution of HER2-low expression from primary to paired metastatic gastric cancer lesions
by: Wen-Zhuo He, et al.
Published: (2025-04-01)

Radiosensitizing effects of pyrogallol-loaded mesoporous or-ganosilica nanoparticles on gastric cancer by amplified ferroptosis
by: Hongwei Wang, et al.
Published: (2023-04-01)

Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study
by: Junxiao Wang, et al.
Published: (2025-07-01)

Potential diagnostic markers and therapeutic targets for DM2 and periodontitis based on bioinformatics analysis.
by: Rong Luo, et al.
Published: (2025-01-01)

AN OVERVIEW OF NANOPARTICLES: METHODS OF OBTAINING, APPLICATIONS AND CHARACTERISTICS
by: Dimitri Botnari, et al.
Published: (2025-09-01)

Neutrophil membrane-coated circular RNA nanoparticles for targeted immunotherapy in HER2-positive breast cancer brain metastasis
by: Yunpeng Liu, et al.
Published: (2025-07-01)

Synergistic HER2-scFv mediated immunotherapy with targeted gemcitabine delivery harnessing biomimetic composite nanoparticles for enhanced metastatic tumor therapy
by: Xinan Wang, et al.
Published: (2025-06-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-04-01)

Serum HER2 Is a Potential Surrogate for Tissue HER2 Status in Gastric Cancer: A Systematic Review and Meta-Analysis.
by: Kecheng Zhang, et al.
Published: (2015-01-01)

Development and Implementation of Modular Turning Dynamometer with Miniature Load Cell
by: Naruebet Khammongkhon, et al.
Published: (2025-02-01)

T2DM: Why Epigenetics?
by: Delphine Fradin, et al.
Published: (2011-01-01)

Immunopharmacology of gastric cancer–deciphering immune cell subset responses and nanoparticle-mediated targeting
by: Yanting Wang, et al.
Published: (2025-05-01)

In-depth profile of biosignatures for T2DM cohort utilizing an integrated targeted LC-MS platform
by: Shurong Ma, et al.
Published: (2025-03-01)

Doxorubicin loaded polylactide nanoparticles functionalized histamine promote apoptosis of human gastric cancer cells AGS
by: Patrycja Jaroniek, et al.
Published: (2025-04-01)

Preliminary Study on the Therapeutic Effect of Doxorubicin-Loaded Targeting Nanoparticles on Glioma
by: Weitu Lan, et al.
Published: (2022-01-01)

NK cell immunopotentiators-loaded nanoliposomes enhance ADCC effect for targeted therapy against HER2-positive breast cancer
by: Ruoxin Du, et al.
Published: (2025-02-01)

Obtaining silver nanoparticles in water solutions of carbonate-ions
by: A. A. Parsaev, et al.
Published: (2010-10-01)

RETRACTED: The expression and clinical significance of PDCD4 and Her-2 in human gastric cancer
by: Yuelou Yang, et al.
Published: (2019-03-01)

Evolution of HER2 expression after neoadjuvant therapy in locally advanced gastric cancer
by: Jun He, et al.
Published: (2025-06-01)

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
by: Yan Zhang, et al.
Published: (2025-12-01)

Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer
by: Jun Yao, et al.
Published: (2025-05-01)

Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report
by: Hiromi Nagata, et al.
Published: (2020-01-01)

Evidence for the existence of Dm0-like Lamin in Sf9 cells
by: Wei Wenqiang, et al.
Published: (2015-05-01)